ConductScience.org, home

Paper1648142

Randomized trial of cyclophosphamide, doxorubicin, and vincristine versus cisplatin and etoposide versus alternation of these regimens in small-cell lung cancer.

Fukuoka M and 7 others. J Natl Cancer Inst, 1991. Cited by 377 papers, by iCite.

Cite this record

ConductScience Library. Randomized trial of cyclophosphamide, doxorubicin, and vincristine versus cisplatin and etoposide versus alternation of these regimens in small-cell lung cancer. Papers, record 1648142. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/1648142

Download JSON
Sources
11 sources
Release
papers-2026-11-12-0.1.0

Paper

PubMed's record of the paper, with iCite's citation figures. No abstract is shown.

Title
Randomized trial of cyclophosphamide, doxorubicin, and vincristine versus cisplatin and etoposide versus alternation of these regimens in small-cell lung cancer.
PubMed
Journal
J Natl Cancer Inst
PubMed
Year
1991
PubMed
Publication types
Clinical Trial, Comparative Study, Journal Article, Randomized Controlled Trial, Research Support, Non-U.S. Gov't
PubMed
Citations, by iCite
377
iCite
Relative citation ratio, by iCite
10.5
iCite
Revised in PubMed
2019-05-10
PubMed

Authors8

The authors in the order PubMed's record lists them, with the ORCID iDs it states.

OrderAuthorForenameKindORCID iD
1Fukuoka MM
2Furuse KK
3Saijo NN
4Nishiwaki YY
5Ikegami HH
6Tamura TT
7Shimoyama MM
8Suemasu KK

Source PubMed

Download CSV of authors

Topics15

NLM's MeSH indexing of the paper, its major topics first.

MeSH termMajor
Antineoplastic Combined Chemotherapy ProtocolsMajor topic
Carcinoma, Small CellMajor topic
Lung NeoplasmsMajor topic
Adult
Aged
Cisplatin
Cyclophosphamide
Doxorubicin
Drug Administration Schedule
Etoposide
Female
Humans
Male
Middle Aged
Vincristine

Source PubMed

Download CSV of topics

Trials1

The trials whose ClinicalTrials.gov record lists the paper, and the trial numbers the paper's PubMed record names.

TrialTitleThe trial lists it asNamed in the paper's record
NCT01752517Vinorelbine and Ifosfamide as Third-line Treatment for Refractory Small Cell Lung CancerResults

Source ClinicalTrials.gov

Download CSV of trials

Cited by87

The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 377 citations.

PMIDTitleJournalYearIn PapersSource
41331590Prognostic role of prognostic nutritional index change in patients with extensive stage small cell lung cancer treated with platinum-based chemotherapy.BMC Cancer2025https://conductscience.org/library/papers/41331590PubMed
37871898The Real-World Outcome of First Line Atezolizumab in Extensive-Stage Small Cell Lung Cancer: A Multicenter Prospective Cohort Study.Cancer Res Treat2024https://conductscience.org/library/papers/37871898PubMed
37175833Small-Cell Lung Cancer-An Update on Targeted and Immunotherapies.Int J Mol Sci2023https://conductscience.org/library/papers/37175833PubMed
36977572Primary tracheal small-cell carcinoma detected 11 months after surgery for pulmonary large-cell neuroendocrine carcinoma: A case report.Thorac Cancer2023https://conductscience.org/library/papers/36977572PubMed
36900334Age-Stratified Analysis of First-Line Chemoimmunotherapy for Extensive-Stage Small Cell Lung Cancer: Real-World Evidence from a Multicenter Retrospective Study.Cancers (Basel)2023https://conductscience.org/library/papers/36900334PubMed
35925272[Small cell lung cancer-Established standards and new approaches].Inn Med (Heidelb)2022https://conductscience.org/library/papers/35925272PubMed
35254612Neuroendocrine Tumors: a Relevant Clinical Update.Curr Oncol Rep2022https://conductscience.org/library/papers/35254612PubMed
34946283Emerging Therapeutic Concepts and Latest Diagnostic Advancements Regarding Neuroendocrine Tumors of the Gynecologic Tract.Medicina (Kaunas)2021https://conductscience.org/library/papers/34946283PubMed
34902832Small Cell Lung Cancer, Version 2.2022, NCCN Clinical Practice Guidelines in Oncology.J Natl Compr Canc Netw2021https://conductscience.org/library/papers/34902832PubMed
34757446Update 2021: Management of Small Cell Lung Cancer.Lung2021https://conductscience.org/library/papers/34757446PubMed
34532422Effectiveness and safety of bevacizumab in extensive-disease small cell lung cancer: a systemic review and meta-analysis.Ann Transl Med2021https://conductscience.org/library/papers/34532422PubMed
34430355Exosomal miR-375-3p breaks vascular barrier and promotes small cell lung cancer metastasis by targeting claudin-1.Transl Lung Cancer Res2021https://conductscience.org/library/papers/34430355PubMed
34164166Role of surgery in a case-control study of patients with clinical stage IIIA small cell lung cancer.J Thorac Dis2021https://conductscience.org/library/papers/34164166PubMed
33568748Clinical considerations for the management of androgen indifferent prostate cancer.Prostate Cancer Prostatic Dis2021https://conductscience.org/library/papers/33568748PubMed
33525370Outcomes of Patients with Pulmonary Large Cell Neuroendocrine Carcinoma in I-IV Stage.Medicina (Kaunas)2021https://conductscience.org/library/papers/33525370PubMed
33521370Current and future strategies in radiotherapy for small-cell lung cancer.J Clin Transl Res2020https://conductscience.org/library/papers/33521370PubMed
32751469Small Cell Lung Cancer from Traditional to Innovative Therapeutics: Building a Comprehensive Network to Optimize Clinical and Translational Research.J Clin Med2020https://conductscience.org/library/papers/32751469PubMed
32706170Atezolizumab in combination with carboplatin and etoposide for heavily treated small cell lung cancer.Thorac Cancer2020https://conductscience.org/library/papers/32706170PubMed
32544169Comparative genomics of high grade neuroendocrine carcinoma of the cervix.PLoS One2020https://conductscience.org/library/papers/32544169PubMed
29535913Current standards for clinical management of small cell lung cancer.Transl Lung Cancer Res2018https://conductscience.org/library/papers/29535913PubMed

See all 87 cited byDownload CSV of cited by

Drugs2

The drugs whose trials, in the Pipelines release, list the paper.

DrugChEMBL IDThe trials list it asTrialsIn Drugs and targetsSource
IFOSFAMIDECHEMBL1024Results1https://conductscience.org/library/drugs/CHEMBL1024ChEMBL
VINORELBINECHEMBL553025Results1https://conductscience.org/library/drugs/CHEMBL553025ChEMBL

Download CSV of drugs

Data dates

The date of each source this release read.

PubMed
2026-11-06
PubMed
iCite
2026-11-05
iCite
PMC's ID file
2026-11-05
PMC's ID file
NIH RePORTER's grant and paper links
2026-11-01
NIH RePORTER's grant and paper links
Trials
2026-11-12
Gene search
2026-11-11
Pipelines
2026-09-18

None in this release

  • Grants
  • Comments and corrections
  • References
  • Genes
  • Data

Sources 11

  • ChEMBL, through Open TargetsCC BY-SA 3.0
  • ClinicalTrials.govNo license stated
  • HGNCCC0
  • iCiteCC BY 4.0
  • NCBI GenePublic domain (US government)
  • NIH RePORTER's grant and paper linksPublic domain
  • Open TargetsCC0 1.0
  • PMC's ID filePublic domain (US government)
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0
Each source's terms
  • ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • ClinicalTrials.govnone stated
  • HGNCCC0: https://www.genenames.org/about/license/
  • iCiteCC BY 4.0
  • NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
  • Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this paper from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/papers/v1/1648142

GET https://conductscience.org/api/papers/v1/1648142/cited_by?page=2